HealthcareServices

Chronic Rhinosinusitis With Nasal Polyps Market 2026–2030: Forecast, Innovation, and Competitive Trends

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic rhinosinusitis with nasal polyps market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Chronic Rhinosinusitis With Nasal Polyps Market between 2026 and 2030?

The chronic rhinosinusitis with nasal polyps market size has experienced strong expansion in recent years. It is anticipated to grow from $4.38 billion in 2025 to $4.78 billion in 2026, registering a compound annual growth rate (CAGR) of 9.0%. This historical growth can be attributed to several factors, including the increasing prevalence of chronic sinus disorders, the wider use of corticosteroid nasal sprays, an increase in ENT specialist consultations, improved access to diagnostic imaging, and heightened awareness of inflammatory sinus diseases.

The market for chronic rhinosinusitis with nasal polyps is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $6.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.0%. Key factors driving this growth during the forecast period include the increasing number of approved monoclonal antibody treatments, greater investment in ear, nose, and throat (ENT) biologics research, the expansion of outpatient sinus surgery options, an intensified focus on preventing recurrence, and a rising patient preference for non-surgical alternatives. Prominent trends expected during the forecast period encompass a wider embrace of biologic therapies for chronic rhinosinusitis with nasal polyps (CRSwNP), increased utilization of minimally invasive surgical methods, a heightened emphasis on managing long-term inflammation, the development of more personalized treatment approaches, and improved integration of diagnostic imaging alongside biomarkers.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17113&type=smp

Which Drivers Are Expected To Impact The Chronic Rhinosinusitis With Nasal Polyps Market During The Forecast Period?

The expanding occurrence of respiratory diseases is set to drive the chronic rhinosinusitis with the nasal polyps market forward. These conditions, which impact the respiratory system including lungs and airways, are escalating due to various factors such as air pollution, smoking, climate change, infections, workplace exposures, and allergies. As more individuals suffer from conditions like asthma and chronic obstructive pulmonary disease (COPD), the frequency of related conditions such as CRSwNP also climbs, leading to a greater need for diagnostic instruments, therapies, and surgical procedures. For example, in December 2023, the National Center for Biotechnology Information, a US-based government agency, estimated that global COPD prevalence will approach 600 million cases worldwide by 2050. Consequently, the rising incidence of respiratory illnesses will fuel the expansion of the chronic rhinosinusitis with nasal polyps market.

How Is The Chronic Rhinosinusitis With Nasal Polyps Market Divided Into Segments?

The chronic rhinosinusitis with nasal polyps market covered in this report is segmented –

1) By Treatment: Medications, Surgical Methods

2) By Route Of Administration: Nasal, Oral, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medications: Corticosteroids (Nasal Sprays, Oral Steroids), Biologics (Monoclonal Antibodies Like Dupilumab)

2) By Surgical Methods: Endoscopic Sinus Surgery (ESS), Polypectomy (Polyps Removal), Balloon Sinuplasty

What Trends Are Reshaping The Dynamics Of The Chronic Rhinosinusitis With Nasal Polyps Market?

Leading companies active in the chronic rhinosinusitis with nasal polyps’ market are prioritizing alternative therapies, such as anti-IL-5 biologics, to enhance patient outcomes and secure a competitive edge. These anti-IL-5 biologics provide targeted treatment that lessens eosinophilic inflammation in conditions like severe asthma and eosinophilic disorders, thereby improving symptom management and the quality of life for patients. For instance, in March 2024, Optinose, a US-based pharmaceutical company focused on developing and commercializing innovative products, obtained U.S. Food and Drug Administration (FDA) approval for its XHANCE. This prescription nasal spray is indicated for the treatment of chronic rhinosinusitis (CRS) in adults, specifically addressing both chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). XHANCE incorporates fluticasone propionate, a corticosteroid that reduces inflammation in the nasal passages. A key characteristic is its unique Exhalation Delivery System (EDS), which allows patients to exhale into the device while applying the spray, thereby enhancing medication delivery deep into the nasal passages and effectively targeting regions where nasal polyps develop and sinuses drain.

Which Key Market Players Are Investing In Expansion And Innovation Within The Chronic Rhinosinusitis With Nasal Polyps Market?

Major companies operating in the chronic rhinosinusitis with nasal polyps market are Pfizer Inc., Roche Holding AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Boehringer Ingelheim International GmbH, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Daiichi Sankyo Company Limited, Olympus Corporation, Eisai Co Ltd, Smith & Nephew PLC, Genentech USA Inc, Mallinckrodt Pharmaceuticals, Lyra Therapeutics Inc, Sunovion Pharmaceuticals, Acclarent Inc., Optinose US Inc, SinuSys Corporation, Biohaven Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-rhinosinusitis-with-nasal-polyps-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Chronic Rhinosinusitis With Nasal Polyps Market?

North America was the largest region in the chronic rhinosinusitis with nasal polyps market in 2025. The regions covered in the chronic rhinosinusitis with nasal polyps market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Rhinosinusitis With Nasal Polyps Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17113&type=smp

Browse Through More Reports Similar to the Global Chronic Rhinosinusitis With Nasal Polyps Market 2026, By The Business Research Company

Rhinoplasty Market Report 2026

https://www.thebusinessresearchcompany.com/report/rhinoplasty-global-market-report

Nasal Polyps Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nasal-polyps-treatment-global-market-report

Nasal Splints Market Report 2026

https://www.thebusinessresearchcompany.com/report/nasal-splints-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795